Teva's PONLIMSI Biosimilar Receives FDA Approval for All Prolia Indications as Q1 2026 Results Show Strong Growth

Key Takeaways

• FDA approved Teva’s PONLIMSI biosimilar across all indications of reference drug Prolia (denosumab) for osteoporosis treatment
• Duvakitug demonstrated clinically meaningful efficacy in ulcerative colitis and Crohn’s disease Phase 2b maintenance trials
• Phase 3 enrollment for duvakitug is currently underway, with Phase 2b induction data accepted for publication in leading journal

---

Teva Achieves Major Regulatory Milestone with PONLIMSI Approval

Teva Pharmaceutical Industries reported strong Q1 2026 financial results driven by significant regulatory achievements and advancing clinical pipeline developments. The Israeli generic drug giant announced that its biosimilar PONLIMSI™ received FDA approval across all indications of the reference product Prolia® (denosumab), marking a major entry into the osteoporosis treatment market.

The FDA approval positions PONLIMSI as a direct competitor to Amgen’s Prolia, which generated billions in annual revenue for treating osteoporosis in postmenopausal women and bone loss in cancer patients. Biosimilars typically offer 15-30% cost savings compared to reference biologics, potentially improving patient access to this critical bone health treatment.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Pipeline Progress Strengthens Teva’s Innovation Strategy

Beyond biosimilar approvals, Teva’s innovative pipeline showed promising advancement with duvakitug, an anti-TL1A monoclonal antibody targeting inflammatory bowel diseases. Phase 2b maintenance data demonstrated clinically meaningful and durable efficacy in both ulcerative colitis and Crohn’s disease patients.

The company’s duvakitug program has gained significant momentum, with Phase 2b induction data accepted for publication in a leading medical journal and Phase 3 enrollment currently active. This positions Teva to compete in the lucrative inflammatory bowel disease market, estimated to reach $12 billion globally by 2028.

Additionally, Teva’s biosimilar candidate targeting Xolair® (omalizumab) was accepted for review by both the U.S. FDA and European Medicines Agency, expanding the company’s biosimilar portfolio into allergy and asthma treatments.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Strategic Positioning

These developments reinforce Teva’s strategic pivot toward higher-value innovative medicines and biosimilars, moving beyond traditional generic pharmaceuticals. The PONLIMSI approval provides immediate revenue opportunities, while the advancing duvakitug program represents potential long-term growth in specialty therapeutics.

Analysts view these achievements as validation of Teva’s R&D investments and regulatory execution capabilities, particularly important as the company continues recovering from previous financial challenges.

---

Frequently Asked Questions

What does PONLIMSI approval mean for patients?

PONLIMSI provides a more affordable biosimilar alternative to Prolia for treating osteoporosis, potentially reducing treatment costs by 15-30% while maintaining equivalent efficacy and safety.

When will duvakitug be available for inflammatory bowel disease?

Duvakitug is currently in Phase 3 trials for ulcerative colitis and Crohn’s disease. If successful, FDA approval could come as early as 2028-2029.

How does PONLIMSI compare to Prolia?

As an FDA-approved biosimilar, PONLIMSI demonstrates equivalent efficacy and safety to Prolia (denosumab) but at a lower cost, approved for all the same indications including osteoporosis treatment.

Related coverage

• Sanofi pipeline pdf: Dupixent, Lantus and 2026 catalysts
• GLP-1 usage statistics show broad uptake and mixed clinical signals
• Vabysmo gains EU approval for retinal vein occlusion: what changes next